A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
for Hemolytic Disease of the Fetus and Newborn
18 locations incl. La Jolla
Sponsor: Janssen Research & Development, LLC
Sex: Female·Age: 18 - 45
Code: NCT05912517·Phase 3·Recruiting·Listed Jun 2023